PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
PMV Pharmaceuticals ended 2023 with $228.6M in cash, reporting a $69.0M net loss, improved from $73.3M. R&D expenses rose to $55.9M for rezatapopt development, while G&A costs fell to $24.2M. The company progresses in the PYNNACLE trial, with Phase 2 starting Q1 2024, and strengthens leadership for clinical advancements.
Reference News
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
PMV Pharmaceuticals ended 2023 with $228.6M in cash, reporting a $69.0M net loss, improved from $73.3M. R&D expenses rose to $55.9M for rezatapopt development, while G&A costs fell to $24.2M. The company progresses in the PYNNACLE trial, with Phase 2 starting Q1 2024, and strengthens leadership for clinical advancements.